Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
As generic and compounded versions of GLP-1 medications become more available and brand-name prices potentially decrease, insurance companies will face less financial incentive to maintain restrictive BMI thresholds
SOURCES: Prime Therapeutics and Magellan Rx Management, analysis, July 10, 2024
Long-term support may include nutrition, protein planning, resistance training, sleep support, behavior changes, and medical follow-up
Other recognised adverse effects include: Injection site reactions (redness, itching) Fatigue (uncommon) Dizziness (uncommon) A modest increase in heart rate has been observed Gallbladder disorders , including cholecystitis and cholelithiasis Diabetic retinopathy complications (particularly in patients with pre-existing retinopathy and rapid improvement in glycaemic control) Acute pancreatitis (uncommon) Dysgeusia (taste disturbance) Increases in pancreatic enzymes (amylase/lipase) Serious allergic reactions, though rare, require immediate medical attention
Energy and mood also typically improve as weight decreases and blood sugar stabilizes, reducing the afternoon energy crashes and mood swings linked to insulin spikes
The landscape is evolving, orforglipron may become available this year, retatrutide in 2027, and brenipatide not until 2028 at earliest
